Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 485.57% | 277.07% | 98.77% | 95.84% | 83.26% |
| Total Depreciation and Amortization | -72.21% | -74.09% | -72.00% | -71.75% | -72.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -247.62% | -208.48% | -54.63% | -69.17% | -69.17% |
| Change in Net Operating Assets | -30.29% | -355.54% | 47.81% | 17.34% | 1.86% |
| Cash from Operations | 96.54% | 86.56% | 88.40% | 72.14% | 56.19% |
| Capital Expenditure | 85.71% | 52.39% | 74.23% | 87.07% | 89.44% |
| Sale of Property, Plant, and Equipment | -- | -75.48% | 34,666.67% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -148.84% | -101.03% | -99.12% | -28.07% | -19.49% |
| Cash from Investing | -71.89% | -33.94% | -98.70% | -26.37% | -18.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -201,300.00% | -89,408.89% | 77.08% | 89.81% | 91.74% |
| Issuance of Common Stock | -- | -85.71% | -85.71% | -99.32% | -99.73% |
| Repurchase of Common Stock | 80.51% | 77.94% | 24.02% | -55.56% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 98.32% | -- |
| Cash from Financing | -33,636.47% | -16,897.83% | 45.39% | -100.20% | -100.21% |
| Foreign Exchange rate Adjustments | 43.41% | -46.36% | -86.85% | 173.07% | 122.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -371.82% | -229.13% | -75.83% | 100.56% | 72.60% |